Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Smith

Otolaryngology/Facial Plastic Surgery Sheboygan, WI Doctor of Osteopathy

NPI 1962617845 CMS profile 419247

1411 N Taylor Dr, Sheboygan, WI 53081

Open in the dashboard

General payments

$500

20 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Smith of Sheboygan, WI is reported in the CMS Open Payments database as having received $500 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Otolaryngology/Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $66 2
2024 General $15 1
2023 General $109 4
2022 General $55 3
2021 General $67 3
2020 General $90 4
2019 General $98 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Smith
  • Otolaryngology/Facial Plastic Surgery median
  • Middle half of Otolaryngology/Facial Plastic Surgery
  • National median

In program year 2025, general payments to Edward Smith were reported at $66. Among 526 Otolaryngology/Facial Plastic Surgery profiles paid that year, the median was $306 and the middle half received between $100 and $757.

Show as a table
Year Edward Smith Otolaryngology/Facial Plastic Surgery median Middle half National median
2019 $98 $237 $98–$548 $163
2020 $90 $118 $46–$265 $114
2021 $67 $179 $69–$469 $132
2022 $55 $212 $94–$520 $149
2023 $109 $225 $97–$552 $160
2024 $15 $285 $111–$707 $164
2025 $66 $306 $100–$757 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $137 5 payments
  2. Intersect ENT, Inc. $85 4 payments
  3. Sanofi-Aventis U.S. LLC $53 1 payment
  4. Regeneron Healthcare Solutions, Inc. $47 2 payments
  5. Genzyme Corporation $36 2 payments
  6. Amgen Inc. $34 1 payment
  7. Medtronic USA, Inc. $33 1 payment
  8. Integra LifeSciences Corporation $32 1 payment
  9. Aerin Medical Inc. $27 2 payments
  10. Medtronic, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $413 18 payments
  2. Education $87 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $125 5 payments
  2. ENTELLUS - XPRESS ENT DILATION SYSTEM $76 2 payments
  3. DUPIXENT Inflammation And Immunology $47 2 payments
  4. SINUVA $44 2 payments
  5. XPRESS ENT DILATION SYSTEM $43 2 payments
  6. PROPEL $41 2 payments
  7. FUSION $33 1 payment
  8. ACCLARENT AERA $32 1 payment
  9. INSPIRA AIR $32 1 payment
  10. RELIEVA SPINPLUS NAV $32 1 payment
  11. Other $96 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

523

Median for Otolaryngology: 297

Drug cost

$9,866

Median for Otolaryngology: $6,314

Branded share of claims

15.9%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Generic 168 $2,750
Azelastine Hcl Generic 72 $2,113
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 21 $1,929
Ipratropium Bromide Generic 32 $901
Omeprazole Generic 46 $868
Ofloxacin Generic 12 $340
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 39 $318
Methylprednisolone Generic 33 $244
Famotidine Generic 17 $161
Prednisone Generic 60 $131

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$60,494

Medicare's payments for the services billed

Medicare patients

250

Average age 73

Services billed

1,454

147 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Chronic kidney disease 31%
Diabetes 28%
Ischemic heart disease 26%
Heart failure 22%
Depression 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology/Facial Plastic Surgery in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record